<DOC>
	<DOCNO>NCT00371254</DOCNO>
	<brief_summary>This study determine whether investigational drug dasatinib effective treatment woman progressive advance triple-negative breast cancer .</brief_summary>
	<brief_title>A Study Dasatinib ( BMS-354825 ) Patients With Advanced 'Triple-negative ' Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>female , 18 old recurrent progressive locally advance , 'triple negative ' metastatic breast cancer paraffinembedded tissue block must available measurable disease prior chemotherapy anthracycline , taxane , ( neoadjuvant , adjuvant , metastatic setting ) 0 , 1 2 chemotherapy metastatic set adequate organ function Metastatic disease confine bone Symptomatic CNS metastasis Concurrent medical condition may increase risk toxicity Unable take oral medication</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Recurrent , locally-advanced , 'triple negative ' metastatic breast cancer</keyword>
</DOC>